Results 81 to 90 of about 15,373 (177)

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

, 2010
peer reviewedPURPOSE: We compared fulvestrant 500 mg regimen with the approved dose of fulvestrant 250 mg per month for treatment of postmenopausal women with estrogen receptor-positive advanced breast cancer who experienced progression after prior ...
Sally Garnett, Didier Verhoeven, Lubos Petruzelka, Bondarenko, Igor N, Torres, Roberto, Francisco Sapunar, Pendergrass, Kelly, José L. Pedrini, Lichinitser, Mikhail R, Di Leo, Angelo, Martin, Miguel, Miguel Martin, Justin P.O. Lindemann, Sapunar, Francisco, Rustem Khasanov, Mikhail R. Lichinitser, Roberto Torres, Jerusalem, Guy, Pedrini, Jose L, Smirnova, Iya, Petruzelka, Lubos, Khasanov, Rustem, Iya Smirnova, Angelo Di Leo, Guy Jerusalem, Garnett, Sally, Verhoeven, Didier, Lindemann, Justin P O, Igor N. Bondarenko, Kelly Pendergrass   +29 more
core   +1 more source

Application of fluorocarbon nanoparticles of 131I-fulvestrant as a targeted radiation drug for endocrine therapy on human breast cancer

Journal of Nanobiotechnology
Background Breast cancer is the most prevalent malignant tumor among women, with hormone receptor-positive cases constituting 70%. Fulvestrant, an antagonist for these receptors, is utilized for advanced metastatic hormone receptor-positive breast cancer.
Li Zhi, Chen Cheng, Luo Jing, Peng Zhi-Ping, Yang Lu, Tian Yan, Wang Zhi-Gang, Yin Guo-Bing   +7 more
doaj   +1 more source

FAM107A loss facilitates TTK‐OPTN‐mediated mitophagy to drive docetaxel resistance in castration‐resistant prostate cancer

Interdisciplinary Medicine, Volume 4, Issue 5, September 2026.
In the progression of docetaxel resistance, downregulation of FAM107A releases its transcriptional repression of TTK, leading to TTK upregulation. TTK enhances the interaction and phosphorylation of OPTN. This activates mitophagy in tumor cells, facilitates clearance of damaged mitochondria, reduces intracellular reactive oxygen species accumulation ...
Yishan Zhang, Fan Zou, Mingdong Wang, Chenyue Wu, Yingwei Xie, Yongjun Quan, Wei Yan, Yupeng Zheng, Lianhua Li, Yuexin Liu, Jian Yu, Hao Ping   +11 more
wiley   +1 more source

Randomised trial of fulvestrant plus vistusertib versus fulvestrant plus everolimus versus fulvestrant alone in hormone-receptor-positive metastatic breast cancer (MANTA)

, 2019
Importance: Randomised clinical trials have demonstrated a substantial benefit of adding everolimus to endocrine therapy. Everolimus inhibits the mTORC1 complex but not mTORC2, which can set off a activating feedback loop via mTORC2.
Lee, K, Conibear, J, Moosa, A, Antonia, P, Schmid, P, Pendergast, A, Makris, A, Ferreira, M, Cortes, J, Kristeleit, H, Nemsdze, G, Kuemmel, S, Schenker, M, Brunt, A, Mathias, Z, Carike, C, Kendall, A, Sarker, S-J, Ruiz, I, Harper-Wynne, C, Cheryl, L, Mahr, K, Chan, S, Sohn, J, Dubey, S, Oelmann, E, Shepherd, C, Sohn, C, Grenier, J, Kelly, M, Brown, J, Marosics, P   +31 more
core  

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

, 2019
BACKGROUND: In an earlier analysis of this phase 3 trial, ribociclib plus fulvestrant showed a greater benefit with regard to progression-free survival than fulvestrant alone in postmenopausal patients with hormone-receptor-positive, human epidermal ...
Beck J. T., Sondhi M., Jerusalem G., Chakravartty, Arunava, Sonke, Gabe S., Nusch A., De La Cruz-Merino L., Esteva, Francisco J, Rodriguez-Lorenc, Karen, Esteva F. J., Sonke, Gabe S, Esteva, Francisco J., Sonke G. S., Slamon, Dennis J., Bianchi G. V., Sondhi, Manu, Wang Y., Im S. -A., Beck, J Thaddeus, Martin, Miguel, Neven P., Chakravartty A., Nusch, Arnd, De Laurentiis M., Bianchi, Giulia V., De Laurentiis, Michelino, Jerusalem, Guy, Petrakova K., Rodriguez-Lorenc K., Bianchi, Giulia V, De la Cruz-Merino, Luis, Beck, J. Thaddeus, Fasching, Peter A, Slamon, Dennis J, Pivot X., Chia, Stephen, Neven, Patrick, Fasching, Peter A., Chia S., Petrakova, Katarina, Taran, Tetiana, Slamon D. J., Pivot, Xavier, Taran T., Martin M., Im, Seock-Ah, Wang, Yingbo, Fasching P. A.   +47 more
core   +1 more source

Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer

Case Reports in Oncology, 2010
We report a case of long-term (9 years) response to 4th-line endocrine treatment with fulvestrant given for advanced breast cancer after no or poor response to prior endocrine therapies.
H. Hawle, D. Hess, A. Mueller, B. Thuerlimann   +3 more
doaj   +1 more source

Advances in FGF/FGFR Signaling: Implications for Disease and Therapy

MedComm, Volume 7, Issue 9, September 2026.
The FGF/FGFR signaling is indispensable for the maintenance of physiological homeostasis and governs multiple biological processes, including embryonic development, bone metabolism, angiogenesis, and neurogenesis, whereas aberrant hyperactivation of this pathway drives the progression of malignancies and autoimmune disorders, including inflammatory ...
Miaoyu Song, Xi Liu, Yang Xiao, Yongsheng Li, Huakan Zhao   +4 more
wiley   +1 more source

Is fulvestrant ("Faslodex") just another selective estrogen receptor modulator?

, 2006
Over the past two decades, much research has focused on developing new antiestrogens that lack estrogen agonist effects and have improved efficacy and tolerability profiles compared with tamoxifen. As all patients eventually become resistant to tamoxifen,
A. HOWELL, Howell, A.; id_orcid
core   +1 more source

Fulvestrant in treatment for metastatic breast cancer [PDF]

, 2019
Background. Metastatic breast cancer is still an incurable disease, and is currently regarded as a chronic process requiring longterm treatment with periodic therapy replacements.
A. A. L’yanova, N. M. Tikhanovskaya, K. A. Novoselova, M. A. Teplyakova, N. A. Abramova, A. E. Storozhakova, L. A. Ryadinskaya, L. Yu. Vladimirova, I. L. Popova, L. K. Strakhov, M. O. Ezhova   +10 more
core   +1 more source

Adding capivasertib to fulvestrant in patients with hormone receptor-positive advanced breast cancer: a cost-effectiveness analysis

Frontiers in Pharmacology
ObjectiveCapivasertib, a novel pan-AKT inhibitor, shows significant antitumor activity against hormone receptor-positive advanced breast cancer. However, its cost-effectiveness of this treatment remains uncertain.
Yitian Lang, Qingqing Chai, Yan Lin, Bin Wu, Xiaoyan Liu   +4 more
doaj   +1 more source